Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53

Blood

Volumn 92, Issue 10, 1998, Pages 3804-3816

  Byrd, John C ^a   Shinn, Charlotte ^b   Waselenko, Jamie K ^b   Fuchs, Ephraim J ^b   Lehman, Teresa A ^b   Nguyen, Phuong L ^b   Flinn, Ian W ^b   Diehl, Louis F ^b   Sausville, Edward ^b   Grever, Michael R ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; FLAVOPIRIDOL; INTERLEUKIN 4; PROTEIN BCL 2; PROTEIN P53;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME ACTIVATION; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMIA CELL; MONONUCLEAR CELL; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL;

EID: 0032533599     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.10.3804     Document Type: Article

References (33)

1. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1997. Ca Cancer J Clin 47:5, 1997
2. Lee JS, Dixon DO, Kantarjian HM, Keating MJ, Talpaz M: Prognosis in chronic lymphocytic leukemia: A multivariate regression analysis of 325 untreated patients. Blood 69:929, 1987
3. Rai KR, Peterson B, Elias L, Shepherd L, Hines J, Nelson D, Cheson B, Kolitz J, Schiffer CA: A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia. A CALGB SWOG, CTG/NCI-C and ECOG Inter-Group Study. Blood 88:141a, 1996 (abstr 552, suppl 1)
4. Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, Diehl D, Sehlenk R, Coy J, Stilgenhauer S, Volkmann M, Galle PR, Poustka A, Hunstein W, Lichter P: P53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell lymphocytic leukemia. Blood 85:1580, 1995
5. El Rouby S, Thomas A, Costin D, Rosenberg CR, Potmesil M, Silber R, Newcomb E: p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82:3452, 1993
6. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P, Fenaux P: p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84:3148, 1994
7. Cano I, Martinex J, Quevedo E, Pinilla J, Martin-Recio A, Rodriquez A, Castaneda A, Lopez R, Perez-Pino T, Hernandez-Navarro F: Trisomy 12 and p53 deletion in chronic lymphocytic leukemia detected by fluorescence in situ hybridization: Association with morphology and resistance to conventional chemotherapy. Cancer Genet Cytogenet 90:118, 1996
8. Robertson LE, Plunkett W, Mcconnell K, Keating MJ, McDonnell TJ: Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 10:456, 1996
9. Aguilar-Santelises M, Rottenberg ME, Lewin N, Mellstedt H, Jondal M: Bcl-2, Bax, and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Int J Cancer 69:114, 1996
10. Thomas A, El Rouby S, Reed JC, Krajewski S, Silber R, Potmesil M, Newcomb EW: Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: Relationship between p53 mutation and bcl-2/ bax proteins in drug resistance. Oncogene 12:1055, 1996
11. McConkey DJ, Chandra J, Wright S, Plunkett W, McDonnell TJ, Reed JC, Keating MJ:. Apoptosis sensitivity in chronic lymphocytic Leukemia is determined by endogenous endonuclease content and relative expression of bcl-2 and bax. J Immunol 156:2624, 1996
12. Panayiotidis P, Ganeshaguru K, Jabbar S, Hoffbrand V: Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukaemia cells in vitro. Br J Haematol 85:439, 1993
13. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR: National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990, 1996
14. Yewdell JW, Gannon JV, Lane DP: Monoclonal antibody analysis of p53 expression on normal and transformed cells. J Virol 59:444, 1986
15. Li B, Greenberg N, Stephens C, Meyn R, Medina D, Rosen JM: Preferential overexpression of mutant p53 in the mammary gland of transgenic mice results in altered lobuloalveolar development. Cell Growth Differ 5:711, 1994
16. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA: Tumor spectrum analysis in p53-mutant mice. Curr Biol 4:1, 1994
17. Senderowicz AM, Headlee D, Stinson S, Lush RM, Tompkins O, Bergan R, Figg WD, Smith A, Sausville EA: Phase I trial of a novel cyclin-dependent kinase inhibitor flavopiridol in patients with refractory neoplasms. Ann Oncol 7s:77, 1996 (abstr 265)
18. Thomas J, Celary J, Tutsch K, Arzoomanian R, Alberti D, Simon K, Feierabend C, Morgan K, Wilding G:. Phase I clinical and pharmacokinetic trial of flavopiridol. Proc Am Assoc Cancer Res 38:222, 1997 (abstr 1496)
19. Senderowicz AM, Headlee D, Stinson S, Lush RM, Figg WD, Pluda J, Sausville EA: A phase I trial of flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. Proc Am Soc Clin Oncol 16:226a, 1997 (abstr 793)
20. Kaur G, Stetler-Stevenson M, Sebers S, Worland P, Sedlacek H, Myers C, Czech J, Naik R, Sausville E: Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst 84:1736, 1992
21. Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ: Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 56:2973, 1996
22. Worland PJ, Kaur G, Stetler-Stevenson MA, Sebers S, Sartor O, Sausville EA: Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Biochem Pharmacol 46:1831, 1993
23. Loseiwicz MD, Carlson BA, Kaur G, Sausville E, Worland PJ: Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun 201:589, 1995
24. Bible KC, Kaufman SH: Flavopiridol: A cytotoxic flavone that induces cell death in noncycling A549 human lung cancer cells. Cancer Res 56:4856, 1996
25. Shapiro GI, Edwards CD, Sausville EA, Rollins BJ: Flavopiridol produces growth arrest and apoptosis in NSCLC cell lines. Proc Am Assoc Cancer Res 38:472, 1997 (abstr 3158)
26. König A, Schwartz GK, Mohammad RM, Al-Katib A, Gabrilove J: The novel cyclin dependent kinase inhibitor flavopiridol downregulates bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood 90:4307, 1997
27. Schwartz GK, Farsi K, Makhija S, Konig A, Gabrilove JL, Spriggs D: Sensitivity of tumor cells to the cyclin dependent kinase inhibitor flavopiridol correlates with loss of bcl-2 expression. Proc Am Assoc Cancer Res 38:472, 1997 (abstr)
28. Parker BW, Kaur G, Nieves-Neira W, Taimi M, Kohlhagen G, Shimizu T, Losiewicz MD, Pommier Y, Sausville EA, Senderowicz AM: Early induction of apoptosis in hematopoetic cell lines after exposure to flavopiridol. Blood 91:458, 1998
29. Krajewski S, Gascoyne RD, Zapata JM, Krajewska M, Kitada S, Chanabhai M, Horsman D, Berean K, Piro LD, Fugier-Vivier I, Liu Y, Wang HG, Reed JC: Immunolocalization of the ICE/Ced-3 - Family protease CPP32 (caspase-3) in non-Hodgkin's lymphomas, chronic lymphocytic leukemias and reactive lymph nodes. Blood 89:3817, 1997
30. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng T-I, Jones DP, Wang X: Prevention of apoptosis by bcl-2: Release of cytochrome c from mitochondria blocked. Science 275:1129, 1997
31. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD: The release of cytochrome c from mitochondria: A primary site for bcl-2 regulation of apoptosis. Science 275:1132, 1997
32. Chandra J, Gilbreath J, Freireich EJ, Kliche KO, Andreeff M, Keating MJ, McConkey DJ: Protease activation is required for glucocorticoid-induced apoptosis in chronic lymphocytic leukemia lymphocytes. Blood 90:3373, 1997
33. Mu X, Kay NE, Gosland MP, Jennings CD: Analysis of blood T-cell cytokine expression in B-chronic lymphocytic leukemia: Evidence for increased levels of cytoplasmic IL-4 in resting and activated CDS T-cells. Br J Haematol 96:733, 1997